ZORBAX Rapid Resolution High Definition
Agilent Product Profile
Agilent is expanding its family of Rapid Resolution High Definition (RRHD) columns with four new phases, including two new C18 stationary phases. Now, there are four C18 phases to work with, so you have more selectivity flexibility in your method development. Furthermore, ZORBAX RRHD Columns help you take your UHPLC analysis further, by providing stability to 1200 bar.
The ZORBAX Eclipse Plus C18 phase features a double endcapped process and unique bonding that delivers exceptional peak shapes across a broad range of analytes. This makes it an exceptional column for method development. Many users of UHPLC are working with analyses that require the highest level of sensitivity and resolution. Alternate C18 phases, such as Extend C18 and Eclipse XDB C18 are desirable because of the additional selectivity refinements they allow.
See the difference ZORBAX RRHD columns can make in your UHPLC Analysis. Go to www.agilent.com/chem/C18choices to download an application note that provides more details about the difference in selectivities.
Jason Link, Product Manager, Jason_Link@agilent.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
